Drug marketing felonies lead FDA prosecutions

Share this article:
"Prior to 1990, most prosecutions for violations of the Federal Food, Drug, and Cosmetic Act (FDCA), were for misdemeanors; since, the most common charges brought against drug companies by the US Department of Justice (DOJ) have been for felonies." So said DOJ consumer litigation director Eugene Thirolf, at a Food and Drug Law Institute Conference on Advertising and Promotion.

He indicated that advertising and marketing of drugs and medical devices represent the most frequent subjects of criminal investigation. He said the rise in criminal cases is related to the fact that federal Medicare/Medicaid programs are paying for a larger percentage of the costs.

Another important “driver” is related to increased reports by “whistle blowers,” or qui tam cases brought under the False Claims Act, Thirolf said.

The HHS reported that whistleblowers filing these suits were awarded $136,756,946 in 2005, up significantly from the $82,867,287 in 2004.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.